A synthetic peptide precursor of angiotensin I
Technical Support & Resources

Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Angiotensinogen (1-14) (human) (trifluoroacetate salt)

Item No. 24989

Product Insert (PDF)Safety Data Sheet (SDS) (PDF)
Technical Information
Formal Name
L-α-aspartyl-L-arginyl-L-valyl-L-tyrosyl-L-isoleucyl-L-histidyl-L-prolyl-L-phenylalanyl-L-histidyl-L-leucyl-L-valyl-L-isoleucyl-L-histidyl-L-asparagine, trifluoroacetate salt
Molecular Formula
C83H122N24O19 • XCF3COOH
Formula Weight
1760.0
Purity
≥95%
Formulation (Request formulation change)
A lyophilized powder
Solubility(Learn about Variance in Solubility)
Formic Acid: 1 mg/ml
SMILES
[H]N[C@H](C(N[C@@H](CCCNC(N)=N)C(N[C@@H](C(C)C)C(N[C@H](C(N[C@]([C@H](CC)C)([H])C(N[C@H](C(N1CCC[C@H]1C(N[C@H](C(N[C@H](C(N[C@@H](CC(C)C)C(N[C@@H](C(C)C)C(N[C@]([C@H](CC)C)([H])C(N[C@H](C(N[C@@H](CC(N)=O)C(O)=O)=O)CC2=CN=CN2)=O)=O)=O)=O)CC3=CN=CN3)=O)CC4=CC=CC=C4)=O)=O)CC5=CN=CN5)=O)=O)CC6=CC=C(O)C=C6)=O)=O)=O)CC(O)=O.FC(F)(C(O)=O)F
InChi Code
InChI=1S/C83H122N24O19.C2HF3O2/c1-11-45(9)67(105-75(118)57(30-48-22-24-52(108)25-23-48)99-77(120)65(43(5)6)103-70(113)54(20-16-26-91-83(86)87)95-69(112)53(84)34-64(110)111)80(123)101-60(33-51-38-90-41-94-51)81(124)107-27-17-21-62(107)76(119)98-56(29-47-18-14-13-15-19-47)71(114)97-58(31-49-36-88-39-92-49)72(115)96-55(28-42(3)4)74(117)104-66(44(7)8)78(121)106-68(46(10)12-2)79(122)100-59(32-50-37-89-40-93-50)73(116)102-61(82(125)126)35-63(85)109;3-2(4,5)1(6)7/h13-15,18-19,22-25,36-46,53-62,65-68,108H,11-12,16-17,20-21,26-35,84H2,1-10H3,(H2,85,109)(H,88,92)(H,89,93)(H,90,94)(H,95,112)(H,96,115)(H,97,114)(H,98,119)(H,99,120)(H,100,122)(H,101,123)(H,102,116)(H,103,113)(H,104,117)(H,105,118)(H,106,121)(H,110,111)(H,125,126)(H4,86,87,91);(H,6,7)/t45-,46-,53-,54-,55-,56-,57-,58-,59-,60-,61-,62-,65-,66-,67-,68-;/m0./s1
InChi Key
VQLJUAMNBAEFFK-FBLPGADJSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Download most recent Certificate of Analysis for this product

    1 mg

    $54

    Add
    Product Description

    Angiotensinogen (1-14), also known as tetradecapeptide (TDP), is a synthetic peptide precursor of angiotensin I (Item No. 24737) that corresponds to amino acids 1-14 of endogenous human angiotensinogen.1 Angiotensinogen (1-14) is cleaved by renin at the Leu-Val peptide bond to release angiotensin I, which is then converted to angiotensin II (Item No. 17150) by angiotensin converting enzyme (ACE) and exerts vasoconstrictive properties.2 Angiotensinogen (1-14) (0.001-1 μM) induces contraction of isolated rat femoral resistance vessels, an effect that is reduced by the angiotensin II receptor partial antagonist saralasin and enhanced by the serine protease kallikrein.3

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Kageyama, R., Ohkubo, H., and Nakanishi, S. Primary structure of human preangiotensinogen deduced from the cloned cDNA sequence. Biochemistry 23(16), 3603-3609 (1984).

    2. Tewksbury, D.A., Dart, R.A., and Travis, J. The amino terminal amino acid sequence of human angiotensinogen. Biochem. Biophys. Res. Commun. 99(4), 1311-1315 (1981).

    3. Kvist, S., Mulvany, M.J., and Aalkjaer, C. Studies of the renin-angiotensin system in the wall of rat femoral resistance vessels. Eur. J. Pharmacol. 198(1), 77-83 (1991).